2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5079 Safety and efficacy of venetoclax plus TACL chemotherapy for adults with relapsed-refractory acute lymphoblastic leukemia: Results of a Phase 2 trial

Francisco Buendia-Pelaez I, MD, Paulo Ugarte I, MD. MsC.2, Francisco Rubio Jr, MD3, Luis Angel Angel Gonzalez Vergara, MD4, Marisa Frausto Alejos, MD5, Jorge Luis Montemayor Mora II, MD6, Carlos de la Cruz-de la Cruz, MD7, Alexander Arturo Grullon Espinal, MD8, Andres Noyola-Perez, MD9, Yessica M. González-Martínez Jr, MD10, Maria Monserrat Reyes, MD11, David Gomez-Almaguer Sr, MD12, Andres Gomez-De Leon Jr, MD13
1 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
2 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
3 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
4 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
5 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
6 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
7 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
8 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
9 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
10 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
11 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
12 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico
13 Hospital Universitario Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico

Background: Relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains a challenge without access to immunotherapy in low- and middle-income countries, where traditional chemotherapy remains the most common strategy. With dismal outcomes, patients need effective but affordable strategies to eventually reach hematopoietic stem cell transplantation (HCT). With the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) regimen, we have achieved promising outcomes in adolescents and adults with ALL.

Objective: To describe the efficacy and safety of outpatient low-dose venetoclax combined with a pediatric-inspired regimen for R/R ALL that includes bortezomib, L-asparaginase, vincristine, mitoxantrone, and dexamethasone (Ven+TACL).

Patients and Methods: Adults with Ph-negative R/R CD19+ B- or T-cell ALL and no prior exposure to venetoclax. Salvage treatment included a combination of venetoclax, vincristine, mitoxantrone, L-asparaginase, dexamethasone, bortezomib, intrathecal chemotherapy, and rituximab in CD20+ patients (NCT07039877). Use of low-dose venetoclax was combined with itraconazole as a potentiation agent. Disease assessment was performed between days 29 and 35 after completion of therapy. The primary outcome was overall response rate. Key secondary outcomes were measurable residual disease (MRD) negativity by next-generation flow cytometry, defined as ≤ 0.001% after salvage therapy completion, achievement of transplantation, the frequency and severity of adverse events, and survival.

Results: Thirteen patients were included, 11 B-ALL and 2 T-ALL patients, with a median age of 21 years (18-47 years), 84.6% were men. 69% (n=9) had active disease, 23% (n=3) had MRDpos disease, and 8% (n=1) had relapsed at least once. The median MRD prior to salvage therapy was 13.4% (0.18-86.4%). Complete remission was achieved by 80% (n=10) of patients, all of which achieved hematologic recovery by the end of treatment. MRD evaluation after completion of salvage therapy was evaluated in 10 patients (77%). The median MRD after completion of salvage therapy was 0.025% (0-61%). 40% (n=4) achieved MRD undetectable (uMRD) status. All uMRD patients (n=4) proceeded to HCT. Cytopenias occurred in 69.2% of patients (n=4 grade 2, n=3 grade 3, n=1 grade 5). 30.8% of patients required RBC and/or platelet transfusions, whereas 38.5% of patients received G-CSF due to severe neutropenia. Therapy was interrupted in 15.4% of patients due to cytopenias. No severe non-hematologic adverse effects were reported. 30.8% of patients required hospital admission and 1 patient required ICU care and died due to septic shock without completing therapy. An additional death occurred at day 13 of treatment due to cardiogenic shock. There were no cases of invasive fungal infections.

Conclusions: The administration of outpatient low-dose venetoclax + TACL for R/R ALL is an effective strategy for R/R ALL that can be delivered in an outpatient setting, demonstrating that it can be an affordable strategy to reach consolidative HCT in low- and middle-income countries. Randomized comparison with alternative standard chemotherapy regimens used in this setting is warranted.

Francisco Buendia-Pelaez I, MD: No relevant conflicts of interest to declare.